Albert Mas-Vidal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Albert Mas-Vidal has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Santos-Juanes
Dermatology Service, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain
3 shared publications - Alejandro García Varona
Department of Cellular Pathology Hospital El Bierzo, Ponferrada, Spain
1 shared publication Altea Esteve‐Martinez
Department of Dermatology
1 shared publicationCristina Galache-Osuna
Section of Dermatology. Hospital de Cabueñes, Gijón, Spain
1 shared publicationJf Toral
Department of Pediatrics and Genetics. “Hospital Universitario Central de Asturias” (HUCA), Oviedo, Spain
1 shared publicationL Miñones‐Suárez
Department of Pediatrics and Genetics. “Hospital Universitario Central de Asturias” (HUCA), Oviedo, Spain
1 shared publication
Latest Publications
- 13 June 2011
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 53 (1) , 70-72
Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor
Psoriatic patients have a higher prevalence of diabetes mellitus type 2 (DM). Since dipeptidyl peptidase IV (DPP‐IV) dysregulation is present in DM and psoriasis, DPP‐IV inhibitors have been proposed as therapeutic agents for both conditions. We report a psoriasiform eruption induced by sitagliptin, a DPP‐IV inhibitor. The role of DPP‐IV in the pathogenesis of DM is well established; however data on psoriatic patients is contradictory. More studies are required to elucidate the effect of DPP‐IV inhibitors and their relationship with DM and psoriasis.
- 13 June 2011
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 53 (1) , 70-72
Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor
Psoriatic patients have a higher prevalence of diabetes mellitus type 2 (DM). Since dipeptidyl peptidase IV (DPP‐IV) dysregulation is present in DM and psoriasis, DPP‐IV inhibitors have been proposed as therapeutic agents for both conditions. We report a psoriasiform eruption induced by sitagliptin, a DPP‐IV inhibitor. The role of DPP‐IV in the pathogenesis of DM is well established; however data on psoriatic patients is contradictory. More studies are required to elucidate the effect of DPP‐IV inhibitors and their relationship with DM and psoriasis.
- 16 August 2010
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 52 (1) , 56-58
Psoriasis induced by cetuximab: A paradoxical adverse effect
Cetuximab, an epidermal growth factor receptor inhibitor, is a chemotherapeutical agent featuring well‐known adverse dermatological effects related to tumour‐response prognosis. In psoriasis, the epidermal growth factor receptor is overexpressed; hence, the expectation would be that an epidermal growth factor receptor inhibitor could improve psoriatic lesions. We report a case of psoriasis induced by cetuximab, which was a surprising adverse effect.
- 16 August 2010
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 52 (1) , 56-58
Psoriasis induced by cetuximab: A paradoxical adverse effect
Cetuximab, an epidermal growth factor receptor inhibitor, is a chemotherapeutical agent featuring well‐known adverse dermatological effects related to tumour‐response prognosis. In psoriasis, the epidermal growth factor receptor is overexpressed; hence, the expectation would be that an epidermal growth factor receptor inhibitor could improve psoriatic lesions. We report a case of psoriasis induced by cetuximab, which was a surprising adverse effect.
- 2 July 2010
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 24 (8) , 978-979
A novel mutation in the FERMT1 gene in a Spanish family with Kindler’s syndrome
- 2 July 2010
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 24 (8) , 978-979
A novel mutation in the FERMT1 gene in a Spanish family with Kindler’s syndrome
- 2 July 2010
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 24 (8) , 977-978
Porphyria cutanea tarda induced by olmesartan
- 2 July 2010
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 24 (8) , 977-978
Porphyria cutanea tarda induced by olmesartan